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Chapter 10  
206 
The studies described in this thesis aimed to provide preclinical evidence for the 
hypothesis that nutritional intervention can be applied for prevention or treatment 
of brain diseases in which inflammation is involved. The main findings from these 
studies are that: 
(I) combining different food components acting on convergent anti-
inflammatory pathways can enhance their anti-inflammatory effects 
(chapter 2 and 4); 
(II) multi-nutrient dietary intervention can modulate inflammation in the 
brain in animal models (chapter 6 and 7).  
In the in vivo part of this study we used an investigational diet, consisting of a 
combination of specific nutrients that were selected based on the literature data and 
our own in vitro experiments. The investigational diet was not only able to modulate 
neuroinflammation, but also to affect the symptoms associated with the investigated 
disease models. However, this concept requires further preclinical investigation 
aimed to further explore its beneficial effects on brain function and disease 
symptoms, such as memory, anxiety or depressive-like behavior. The ultimate goal 
of this research would be to apply the nutritional concept in a clinical trial. Since all 
nutrients investigated in this thesis are part of our regular diet, the nutritional 
intervention could be readily applied in clinical trials without the necessity of 
toxicological studies.  
 
1. In vitro investigation of combinations of anti-
inflammatory nutrients  
Epidemiological studies demonstrated positive effects of certain diets on the 
incidence of several inflammation-related diseases [1–3]. Consequently, there is 
increasing interest in identifying the specific food components that are responsible 
for these effects.  
Interaction of individual nutrients with different signaling pathways can increase 
the anti-inflammatory effect of a dietary supplementation, as was discussed in 
chapter 2, 3 and 4. Individual components can complement each other, resulting in 
additive or even synergistic effects. As a result, lower concentrations of the active 
nutrients can be used to achieve a beneficial effect. Some food components, like the 
fat-soluble vitamins A, D, E and K, can be toxic when used in high concentrations. 
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Multi-nutrient supplementation with low concentrations of individual nutrients will 
be a much safer approach, than administration of high doses of a single 
component.  
The approach of in vitro screening of nutrients presented in chapter 2 and 4 can also 
be applied for new compounds with possible anti-inflammatory properties. 
Evaluation of nutrients on immortalized cell lines allows testing of a large number 
of compounds and combinations thereof. The use of immortalized microglia cell 
lines, rather than isolated primary microglia, in the early steps of evaluation of new 
components is recommended for practical (faster screening) and ethical reasons (no 
animals have to be sacrificed for the isolation of primary microglia). 
For the characterization of possible additive effects of different combinations of 
compounds, we proposed to test mixtures of substances at concentrations where 
they do not exert significant effects on their own (sub-effective). This approach 
increases the detection window of possible additive or synergistic anti-inflammatory 
effects by the combination of nutrients. The ingredients can be chosen based on 
their individual mechanism of action. 
 
2. Elucidation of mechanisms of action of food 
components 
In order to design an effective nutritional intervention, evaluation of the 
mechanism of action of nutrients is an indispensable step to optimally benefit from 
the complementary effects of different components. 
From the nutrients investigated in this study, the mechanism of action of vitamins 
A, B, D and fatty acids have been extensively investigated. On the other hand, rice 
bran components have been scarcely studied so far and consequently little is known 
about their anti-inflammatory mode of action. A study can be designed to gain 
more insight in the mechanisms of action of these and other nutrients. This can be 
achieved in vitro or in vivo by:  
 
2.1. Analysis of the metabolites and metabolic pathways of the nutrients.  
The anti-inflammatory effect of a nutrient can be due to a direct effect of the 
nutrient itself, but can also be due to the effect of an active metabolite. Therefore, it 
is important to characterize the metabolism of the nutrient. The type of analysis 
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will depend on the chemical characteristics of the nutrient and its metabolites. 
Since many anti-inflammatory food components are lipids (e.g. fatty acids, rice 
components), a lipidomic analysis can be applied in which lipid components can be 
separated and analyzed. Separation of lipid components from cell, tissue or blood 
samples can be done with chromatographic techniques like (I) gas chromatography 
(GC), which can be used for the analysis of small molecules, (II) high performance 
liquid chromatography (HPLC) [4], or (III) thin layer chromatography (TLC). 
Separated lipid components can be further analyzed with mass spectrometry (MS). 
Combination of chromatography and MS is widely used for lipid characterization 
in plasma, tissue (e.g. brain) or cerebrospinal fluids. Moreover, since the transport, 
biosynthesis and modification of lipids involves proteins, combining lipidomics with 
proteomics allows better understanding of metabolic pathways of the lipids [5]. 
Proteomic analysis can be performed with SDS-PAGE (sodium dodecyl sulfate 
polyacrylamide gel electrophoresis) followed by MS analysis of separated proteins 
[6]. 
Another method to analyze metabolism is to label the compound of interest (in this 
case, nutrient) with a radioactive isotope, such as 3H or 14C [7–9]. This allows 
tracking the nutrient and its metabolites in the tissues, blood or urine.  
2.2. Analysis of the interaction of the nutrient or their active metabolites 
with receptors and signaling pathways 
After obtaining information about the metabolism of the nutrient, the anti-
inflammatory properties of the main metabolites can be screened to determine if 
metabolites might have a therapeutic effect. Next, the interaction of the nutrient or 
its active metabolite with specific receptors and signaling pathways can be 
investigated. 
2.2.1. Binding studies 
Binding studies with selective competitors may be applied in order to test the 
interaction of nutrients with specific receptors involved in relevant anti-
inflammatory pathways. Alternatively, the pharmacological response of a nutrient-
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2.2.2. Analysis of expression/concentrations of signaling molecules 
Analysis of gene expression or proteomics allows detection of the increased 
expression of specific receptors or signaling molecules following the treatment with 
a particular nutrient. These receptors can be further investigated in cells and tissues 
by western blot, immunohistochemistry or flow cytometry.  
2.2.3. Inhibition of key mediators in specific signaling pathway 
The interaction of the nutrient with a receptor and the resulting physiological 
effects can be explored in vitro and in vivo by inhibition of receptor signaling by 
chemical blocking with a specific antagonist, or inhibition of receptor expression by 
gene knockout or treatment with antisense RNA. Chemical inhibitors provide a 
very effective approach, as was demonstrated for the interaction of vitamin A with 
retinoic acid receptors (RAR) in this project (chapter 2). Chemical inhibitors, 
however, may not be specific to only one target. Therefore, this data may need to 
be confirmed with more specific approaches, such as gene knockout or antisense 
RNA targeting specific receptors. 
In vitro findings on receptor interactions need to be validated in animal models, 
because the effects observed in vitro may be compensated by alternative mechanisms 
in vivo. For example, previous studies with chemical inhibitors have demonstrated 
that partial inhibition of RAR can be compensated for in vivo by increasing 
RARβ  and RARγ  expression [10]. In contrast, knockout of RAR did not induce 
any compensation mechanisms. Therefore, a similar approach as for in vitro studies 
(chemical blocking, gene knockout or antisense RNA) could be applied in vivo to 
confirm the data from cell studies. 
 
3. Animal studies with dietary interventions  
The anti-inflammatory properties of nutrients observed in vitro can be validated in 
animal models. Some in vitro results may be false positive for nutrients forinstand as 
they might not sufficiently penetrate brain tissue in vivo. On the other hand, some in 
vitro data may also be false negative for nutrients which do not act directly on 
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3.1. Timing 
Nutrition can be considered as a prophylactic tool for prevention of brain diseases, 
as suggested by the outcomes from epidemiological studies on the effect of diets on 
the incidence of brain diseases [1-3]. However, preclinical investigation show that 
dietary intervention can also be applied after the onset of disease and still have a 
therapeutic effect on disease progression. Therefore, in this project we investigated 
both prophylactic and therapeutic treatment designs with the investigational diet 
(as described in chapter 6 and 7). Both strategies resulted in beneficial effects and 
therefore both approaches should also be included in the future preclinical studies.  
3.2 Type of intervention 
The two main approaches to investigate the effects of the diet in vivo are: (I) 
supplementation or (II) depletion/elimination of the specific nutrients. Both 
approaches may provide important information about the role of specific nutrients 
in healthy animals and during disease pathology. Depletion/elimination studies 
may provide information about the role of essential nutrients during inflammation. 
On the other hand, supplementation studies can provide information on the 
possible use of increased concentrations of nutrients as a prophylactic or 
therapeutic tool.  
3.3. Toxicity 
Although normal concentrations of nutrients can generally be used safely in 
humans, for some nutrients, in particular those that have been poorly investigated 
(such as rice bran components or novel plant components), are applied in high 
doses or can potentially accumulate in the organism (such as fat-soluble vitamins), 
toxicity studies might still be required. Toxicity can be determined in animal 
studies in order to identify possible side effects of the substances and to determine 
the dosage window that can be used safely.  
3.4. The choice of the disease model 
The primary criteria for choosing of disease model for preclinical investigations is 
its suitability for translation to the human pathology in which neuroinflammation is 
involved. Therefore, we have chosen models mimicking the human pathology. 
Photothrombotic stroke model in rats mimics the mechanism of the onset of this 
disease in humans, the formation of thrombi which blocks the blood supply in part 
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of the brain. In postoperative cognitive decline model in rats we mimic the general 
surgery in humans which may lead to the cognitive decline. 
 
3.4.1. Severity of inflammation 
 
The animal models used for anti-inflammatory diet intervention must be validated 
for the presence of inflammation and there should be evidence that 
neuroinflammation is instrumental in disease progression. Moreover, the animal 
models used for dietary intervention should be characterized by relatively low 
severity. We expect that the effect of a nutritional intervention might be subtle and 
therefore may not be able to significantly suppress excessive neuroinflammation 
due to a possible ceiling effect. Choosing animal models with low severity increases 
the chances of successful modulation of inflammatory process with a dietary 
intervention (Weber’s law). Although it seems to be an optimal approach for proof-
of-concept study, the results need to be confirmed in a model that more closely 
mimics the extent of inflammation in patients. 
3.4.2. Behavior 
To complement our data on the modulation of neuroinflammation, more emphasis 
on behavioral improvement could be put in future experiments. The ultimate goal 
of anti-inflammatory dietary intervention is to improve brain function, ameliorate 
disease symptoms and stop disease progression via modulation of 
neuroinflammation. This can be achieved by designing adequate behavioral 
studies. Behavioral tests are in general more sensitive to confounding factors (and 
therefore the data contain more noise) than imaging or in vitro tests and therefore 
larger sample sizes may be required. For example, in chapter 6 we investigated 
spatial memory impairment after abdominal surgery in rats, but did not find 
statistically significant abnormalities with a sample size of n=8, whereas PET 
imaging and immunohistochemistry did reveal significant effects. The sample size 
in this study was calculated based on the imaging data, not on behavioral tests. 
Therefore, in the future studies, the sample size should not only be estimated for 
imaging, but also for the behavior tests. The exact sample size could be estimated 
based on the results of the abdominal surgery obtained in this study.  
Another parameter that is important for model selection is the temporal 
progression of symptoms. Behavioral symptoms that persist over a longer period of 
time will help to investigate the effect of the diet, especially if the dietary 
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intervention is applied after the disease onset. For example, in chapter 7, we 
observed that the severity of our photothrombotic stroke model was relatively low 
and that lateral motor impairment was only present up to three days following 
ischemia. More persistent lateral motor impairment (as observed in a slightly more 
severe stroke model) may increase the possibility to detect the modulation of this 
symptom by dietary intervention in the future studies. Since the severity of 
photothrombotic model can be modulated by the time of irradiation, we could 
consider increasing the irradiation time and therefore, aggravating the resulting 
brain damage in this model in order to obtain longer lasting behavior effects.  
3.4.3. Disease models for psychiatric disorders 
In this thesis, we investigated the dietary intervention in a POCD and a stroke 
model. Since neuroinflammation is believed to be involved in many psychiatric and 
neurodegenerative disorders, the investigational diet could also be tested in other 
animal models in which the presence of neuroinflammation has been established. 
Several animal models of mood disorders or cognitive decline can be considered for 
future dietary intervention. Some examples are: lipopolysaccharide (LPS) induced 
anxiety- and depressive-like behavior in mice or rats [11,12], repeated social defeat-
induced depressive-like behavior [13], unpredictable chronic mild stress (UCMS) 
[14], cognitive decline in aged rats (naïve or subjected to the surgical procedures 
exacerbating the cognitive decline) [15]. From these models, LPS-induced anxiety- 
and depressive-like behavior might be too severe, since LPS is endotoxin which 
causes a very strong pro-inflammatory reaction. Moreover, it leads to sickness 
behavior for which the symptoms overlap with the depressive symptoms. Social 
defeat and unpredictable chronic stress may better reflect the mechanism of 
anxiety- and depressive-like behavior in humans which is not related to sickness 
behavior. However, a complication for a dietary intervention in these models is that 
they are characterized by anhedonia, substantial decrease in food intake and body 
weight. It is therefore difficult to maintain the same level of food intake between 
experimental groups and to ensure sufficient intake of the active components from 
the diet. This can be overcome with intravenous injections of nutrients. Cognitive 
decline in aged animals seem to be the best model to study the effect of diet on 
neuroinflammation because (I) ageing is related to chronic mild neuroinflammation 
(II) maintaining sufficient food intake may be more feasible in these models, since 
even after the abdominal surgery, the weight loss in aged animals does not exceed 
10% [16]. 
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Psychiatric disorders and ageing in humans are often associated with depletion of 
substantial nutrients. Therefore, nutritional supplementation in animals receiving 
complete control diet differs from the clinical situation in which patients may be 
depleted from some important dietary components. An option to overcome these 
differences and to increase the likelihood of finding beneficial effects could be to 
apply nutrient deprivation before dietary intervention in the animal model, 
analogous to a likely clinical situation. 
3.4.4. Disease models of peripheral inflammation 
Epidemiological studies suggest an association between psychiatric disorders and 
diseases with strong peripheral inflammation [17]. For example, a higher incidence 
of depression is observed in patients with colitis. It is believed that 
neuroinflammation can be induced by peripheral triggers and thus could be the key 
player that connects the comorbidity between peripheral inflammation and brain 
diseases. However, further studies need to be performed in order to confirm the 
presence of neuroinfammation in response to for example colitis. This can be done 
by implementing animal models for these peripheral inflammatory diseases (e.g. 
DSS-induced chronic colitis) and investigating the brain with sensitive methods to 
characterize the markers of inflammation (immunohistochemistry, flow cytometry, 
western blot, qPCR or imaging methods). If neuroinflammation can be confirmed, 
animal models of for example colitis could be applied for anti-inflammatory dietary 
intervention. This however will need discrimination between the direct effects of 
the anti-inflammatory diet on neuroinflammation and the indirect effect 
(ameliorating peripheral inflammation and therefore induction of less severe 
neuroinflammation). The first step for this discrimination would be to monitor 
disease progression in peripheral tissues. In case the diet will affect disease 
progression and peripheral inflammation, further discrimination can be applied. 
For example, a positive control with an anti-inflammatory treatment injected into 
the brain or transgenic models with impaired microglia response can help to assess 
selectively the effect of inhibition of neuroinflammation. 
3.4.5. Disease models for neurodegenerative disorders 
Neuroinflammation is not only believed to play a role psychiatric disorders and 
peripheral inflammatory diseases, but is also involved in the development of 
neurodegenerative diseases, like Alzheimer’s disease (AD) and Parkinson’s disease 
(PD). Animal models for neurodegenerative diseases could therefore be considered 
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for future dietary intervention studies. Several models of neurodegenerative 
diseases with proven neuroinflammation have been described. Some examples are: 
the colchicine induced rat model of AD [18], amyloid-induced AD [19], transgenic 
AD models [20], rotenone-induced PD [21], alpha-synuclein-induced PD [22], and 
6-hydroxydopamine-induced PD [23]. Modulation of the severity of 
pharmacologically-induced models is feasible by changing the dose of a toxin. 
Therefore these models seem to be more appropriate for dietary intervention which 
requires low severity.  
Many preclinical studies on neurodegenerative disorders are performed in 
transgenic models. In patients, however, genetics are not the only cause of 
neurodegenerative diseases, as most of these disorders are triggered by multiple 
factors. Familial AD, for example, accounts for only approximately 5% of the AD 
cases [24]. Similarly, only approximately 10% of the PD patients have a family 
history of this disorder [25]. This suggests an important role of environmental 
factors in the development of AD in PD in the majority of patients. It is believed 
that neurodegenerative diseases are caused by complex interactions between 
environmental and genetic factors. Therefore, using pharmacologically-induced 
models, or a combination of a transgenic model with a pharmacological trigger, 
may be more appropriate [24]. Intracerebral injection of a drug may cause by itself 
strong inflammation and sickness behavior. Therefore, models in which toxin can 
be delivered intravenously or intraperitoneally seem to be a better approach (e.g. 
systemic rotenone-induced PD) [26]. However, given the complexity of the 
neurodegenerative diseases, it is unlikely that one model will resemble all the 
diseases characteristics [27]. The optimal approach would be to choose a model 
which most closely resembles the pathology observed in patients in order to ensure 
highest changes of success when translating the preclinical results to clinical studies. 
However, as discussed above, models usually do not ideally represent the clinical 
situation and only mimic some specific aspects of the disease. To compensate for 
this, multiple complementary models can be used that together cover all 
characteristics of the disease.   
 
4. Human studies on the impact of nutrition 
4.1. Observational human studies: Epidemiological studies 
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Lifestyle, which includes a person’s diet, has been recognized as an important 
modifiable factor affecting the incidence of diseases in which neuroinflammation 
may play a role. Prospective studies, in which the dietary patterns and disease 
incidence of a cohort of subjects are assessed for a long period of time, provide 
large datasets on the effect of diet on the incidence of brain diseases in which 
(neuro)inflammation may be involved [1–3]. There are two main methods for 
assessment of food intake in the epidemiological studies: (I) objective observation 
and (II) subjective reporting by the participant [28]. Objective observation can be 
performed by collection of food samples for analysis or by direct observation by 
trained staff. These methods are difficult to apply for large cohort studies. 
Subjective reporting methods include 24-hour dietary recall, dietary recording with 
a questionnaire and reporting of dietary history. These methods provide detailed 
data about food intake, but they are time-consuming and subject to bias, as they 
depend on the memory of the respondent. As another method for subjective 
reporting, food frequency questionnaires allow simple assessment of regular daily 
food intake in large cohorts in a cost-effective and time-effective way. This method 
might be less accurate as compared to others and requires validation of the 
questionnaire used for the study, but it seems to be a practical approach for the 
large epidemiological studies [28].  
Epidemiological studies serve to identify dietary factors that have an impact on 
disease incidence and disease progression. The factors identified in epidemiological 
studies should be further tested in preclinical investigations and clinical trials [29], 
in order to confirm a causal relationship. 
4.2. Experimental human studies: Randomized clinical trials (RCT) 
Randomized clinical trials (RTC) allow testing of the efficacy of nutritional factors 
in similar groups of subjects. RCT should be used to confirm the hypotheses 
derived from epidemiological studies and/or preclinical investigations in cells and 
animal models. There are challenges in clinical trials on dietary interventions that 
differ from clinical trials on pharmaceutical drugs. For example, dietary 
intervention is:  
- more sensitive to external variables 
- formed by heterogeneous mixtures (e.g. food or supplemented food products, in 
contrast to a single pharmaceutical compound in pharmacological trials) 
- multi-targeting (since the dietary intervention consists of multiple active 
components) 
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- consumed throughout the day, resulting in difficulties to standardize the intake. 
Moreover, participants in dietary intervention trials are continuously exposed to 
easily accessible food, which may contain the same nutrients as those included in 
the intervention and therefore change the dosage of the intervention.  
During dietary interventions, it is important to take the background food intake 
(before and during the intervention) into account and to closely monitor food intake 
during the experiment, which can be done prospectively by direct observation, food 
records, or food diary; or retrospectively by 24h diet recall, or questionnaires. The 
retrospective methods highly depend on the accurate memory and reliability of the 
respondent and on the ability of the respondent to estimate portion size [30]. For 
hospitalized patients, food intake might be easier to control and record.  
Placebo-controlled, double-blind studies are more difficult to design for dietary 
interventions than for pharmaceutical drugs, especially in case of interventions 
which aim to change the whole diet. Placebo-controlled studies are more feasible if 
a dietary supplement with a specific (combination of) nutrient(s) is tested. 
4.3. Diet formulation 
The formulation of a dietary intervention is highly dependent on the nature of the 
investigational nutrients. The diet investigated in this thesis was based on standard 
laboratory animal chow AIN-93G [31] and therefore adapted for the investigation 
in mice and rats. Applying the same dietary concept in clinical trials would require 
designing and preparation of a formulation appropriate for use in humans. 
Supplementation in humans can be applied in diverse formulations, including 
tablet, capsule and liquid. Since our dietary intervention is multi-nutrient and 
contains both water-soluble components (B vitamins, amino acids, carbohydrates) 
and fat-soluble components (DHA, EPA, vitamin A and D), the best approach 
would be to apply them in a form of emulsion.  
Dosage of the active ingredients will need to be extrapolated to humans based on 
the daily intake recommendations and toxicity of some ingredients (e.g. fat-soluble 
vitamins). This should be accompanied with measurement of absorption of active 
ingredients from the formulation in humans.  
4.4. Selection of a patient cohort 
Neuroinflammation is believed to be involved in the development of several 
psychiatric and neurodegenerative disorders. It is also believed to mediate 
comorbidity between peripheral inflammation and brain diseases. Therefore, a 
 Future perspectives 
217 
10 
variety of patients with psychiatric or neurodegenerative diseases can be considered 
for the treatment with anti-inflammatory dietary intervention. As examples of 
disorders with neuroinflammation, we focus the discussion here on the two 
disorders, for which we described promising preclinical results in this thesis: 
postoperative cognitive decline and stroke. 
4.4.1. Postoperative cognitive dysfunction 
Cognitive dysfuction forms a category of brain disorders which are hypothesized to 
be triggered by neuroinflammation. In fact, there is substantial preclinical evidence 
that postoperative cognitive dysfuction is triggered by neuroinflammation [32]. Our 
study with dietary intervention for POCD in rats not only confirmed the presence 
of neuroinflammation in rats subjected to surgery, but also provided evidence for a 
therapeutic effect of the diet on neuroinflammation and other disease symptoms 
caused by the surgery. Although preclinical studies and indirect evidence in 
humans suggested an inflammatory component in the pathology of POCD, the 
presence of neuroinflammation has not been demonstrated directly in the brain of 
patients with cognitive decline yet.  
Clinical studies to detect neuroinflammation or to investigate the effectiveness of an 
anti-inflammatory diet intervention for POCD will be challenged by the high 
variability in the condition of the patients before and after surgery, in the nature of 
the surgical intervention and in concomitant diseases. Therefore, proper inclusion 
criteria need to be established (for example, the same type of intervention, age 
range, no concomitant diseases). Moreover, this type of studies would require a big 
sample size, since POCD does not develop in all patients subjected to the surgical 
procedure. Persisting POCD (longer than 3 months post-surgery) is seen in 
approximately 10% of patients over 60 years of age [32,33]. Since the occurrence 
of POCD is the highest in this group of patients (>60), this group might be optimal 
for future intervention studies. However, in elderly patients also the occurrence of 
concomitant diseases is highest and this may complicate the selection of 
homogenous group for the study. 
Since surgery can be planned, the designing of both preventive and postoperative 
dietary intervention is feasible in this patient group. 
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4.4.2. Stroke 
The presence of neuroinflammation has been well described in animal models of 
stroke. Human studies have shown increased levels of activated leukocyte cell 
adhesion molecule (ALCAM), a marker of neuroinflammation, in stroke patients. 
High levels of ALCAM were correlated to increased long-term mortality in stroke 
patients [34]. [11C]PK11195 PET studies revealed the presence and spatiotemporal 
changes of neuroinflammation following cerebral ischemia [35]. Animal studies 
have shown not only the presence of neuroinflammation following cerebral 
ischemia, but also the therapeutic effects of anti-inflammatory treatment on disease 
progression after stroke.  It is believed that chronic and persistent 
neuroinflammation in the area surrounding the lesion (penumbra) can lead to 
further neuronal damage and therefore increase the lesion size. Therefore, anti-
inflammatory treatment should aims to ameliorate or prevent further neuronal 
damage following ischemia. Therefore, stroke patients are a good target group for 
the new anti-inflammatory treatment strategies. Some clinical studies have 
demonstrated a positive impact of anti-inflammatory treatment on the patients 
recovering from stroke [36–38], while epidemiological studies demonstrated a 
promising effect of anti-inflammatory diet in the prevention of stroke [39]. 
Therefore, a clinical study to investigate preventive and therapeutic effects of anti-
inflammatory diet in humans may be a promising approach. 
Testing the possible prevention of stroke in a clinical trial would require a long-
term follow-up. This implies that the dietary intervention would have to be applied 
daily for a long period of time. Therefore, it seems to be more feasible to perform 
observational study on the preventive impact of the diet on stroke incidence, as it 
was done before [39]. 
Clinical trials could more easily be applied to test the efficacy of anti-inflammatory 
diet during the recovery phase after the onset of ischemia in patients who suffered 
from cerebral ischemia. In this case, it will also be challenging to achieve a 
homogeneous patient cohort, because of the possible concomitant diseases and big 
variability in brain damage between the subjects. It is therefore necessary to 
correlate the outcome of the dietary intervention to the progression of brain 
damage. A solution could be to apply a within-subject design in which patients after 
stroke would be scanned twice, before and after dietary intervention. Furthermore, 
it could be assessed whether the brain regions with neuroinflammation (detected on 
the baseline scan with for example [11C]PK11195PET) could be salvaged. Brain 
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damage could be assessed with for example [18F]FDG PET, [11C]flumazenil PET 
or MRI.  
In conclusion, dietary intervention in POCD seems to be more feasible to design 
and plan. Both pre-surgical and post-surgical treatment can be applied. However, a 
big sample size is necessary for this study, because only a small fraction of the 
patients will develop chronic cognitive decline. 
Diet intervention in stroke patients can be applied only after the onset of ischemia. 
However, the possibility of applying smaller sample size can facilitate the study, 
since all patients will develop neuroinflammation. 
 
5. PET imaging 
5.1. The role of PET in nutritional research 
As it has been reviewed by others [40], a large variety of PET tracers have been 
used in food science. These tracers include radiolabeled amino acids, peptides, 
proteins and antibodies, lipoproteins, fatty acids, lipids, nucleotides, trace elements, 
carbohydrates, plant secondary metabolites, vitamins and vitamin derivatives. For 
example, a vitamin D3 receptor (VDR) ligand tracer ([26,27-11C]dihydroxyvitamin 
D3) was developed. In a similar way, a potential tracer to investigate other relevant 
receptors could be designed. These tracers would allow determination of the 
receptor occupancy following diet intervention. For example, a tracer that binds to 
retinoic acid receptors could help to elucidate the anti-inflammatory mechanism of 
vitamin A in vivo and thus to confirm our in vitro results. A PET study with 
radiolabeled food components would help to elucidate how each of the components 
of the diet is interacting with its molecular target. PET imaging may also help to 
investigate the metabolism and accumulation in tissue of specific nutrients, as it was 
done with amino acids (e.g. 11C-labelled methionine was used for study of 
distribution and metabolism of methionine) or fatty acids and lipids (for example 
11C and 18F-labelled fatty acids applied to investigate fatty acid kinetics and tissue 
uptake) [40,41]. PET imaging may be very helpful in the investigation of 
metabolism and uptake of nutrients in brain, allowing the investigation in human 
subjects. For example, a human study with 11C-labelled docosahexaenoic acid, 
allowed to characterize incorporation of DHA into brain tissue [40]. These studies 
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could help to design an effective dietary intervention and to estimate the doses of 
nutrients required for achieving a sufficient concentration in human brain tissue. 
In general, a disadvantage of this approach is that separate tracers need to be used 
for each individual nutrient. 
PET imaging of neuroinflammation may be a suitable alternative to monitor the 
effectiveness of an anti-inflammatory diet in patients. To our knowledge, PET 
studies on effect of anti-inflammatory diets in humans have not been performed 
yet.  
5.2. Peripheral inflammation 
In clinical practice, [18F]FDG is successfully used to image peripheral 
inflammation. [18F]FDG PET imaging is not suitable for measurement of 
neuroinflammation because of the high physiological uptake of this tracer in the 
brain. Therefore, other tracers have to be used for brain imaging of inflammation, 
for example TSPO tracers. 
5.3. Neuroinflammation 
The most widely used TSPO tracer for the measurement of neuroinflammation, 
[11C]PK11195, has a low signal-to-noise ratio, which hinders the detection of subtle 
changes, especially in small animals. In fact, [11C]PK11195 PET imaging was able 
to detect neuroinflammation caused by abdominal surgery, but could not detect 
any effect of dietary intervention, as was described in chapter 6 of this thesis.  
Therefore, new PET tracers with improved image properties have been developed, 
such as [11C]PBR28, [18F]PBR06, [18F]FEPPA, [11C]DAA1106, [11C]DPA713, 
[18F]DPA714 and [18F]PBR111. These tracers have a higher binding affinity for 
the TSPO. This facilitates the detection of subtle changes in TSPO expression in 
animals. However, in humans, the binding affinity of the second generation TSPO 
PET radioligands is strongly affected by TSPO receptor polymorphism in 
Ala147Thr. This results in a trimodal distribution in binding affinity of the tracer 
(low, medium and high affinity) [42,43]. Although testing for polymorphism allows 
exclusion of subjects with the low-binding polymorphism, this requires additional 
procedures and may introduce a significant bias, as the impact of the 
polymorphism on the process of interest is generally not known. For this reason, 
development of new tracers for new targets involved in neuroinflammation in 
humans might be the best approach. At the current stage, we still consider 
[11C]PK11195 as the best tracer to investigate neuroinflammation in humans, since 
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its uptake does not depend on TSPO receptor polymorphism. The sensitivity of 
[11C]PK11195 PET imaging can be increased by applying full quantification of 
receptor binding with pharmacokinetic modelling. At the moment, [11C]PK11195 
PET imaging seems to be the best approach for clinical investigations, while in pre-
clinical studies also the second generation TSPO PET radioligands can be used, 
since they are not affected by polymorphism in mice and rats. 
5.4. New tracers for PET imaging of peripheral and central inflammation 
Apart from TSPO receptors and glucose metabolism, also other targets are 
considered for the measurements of inflammation in central and/or peripheral 
tissues. These other targets include membrane markers on inflammatory cells (e.g. 
cannabinoid receptors), inflammatory cytokines (e.g. cyclooxygenase, matrix 
metalloproteinases, IL-2, TNF) and inflammation-related targets on blood vessels 
(e.g. integrin receptor, vascular adhesion protein-1, vascular cell adhesion 
molecule-1, vessel permeability). This has been reviewed in more detail elsewhere 
[42].  
In general, a disadvantage of TSPO receptor imaging is that these methods do not 
allow distinction between microglia, astrocytes and infiltrating macrophages. This 
could be solved with tracers targeting specifically one cell type. For example 
[11C]deprenyl, a tracer that targets monoamine oxidase B (MAO-B) which is 
specifically overexpressed by activated astrocytes, was used to detect astrogliosis in 
human patients with AD [44]. Furthermore, it is not known whether TSPO is 
overexpressed by both M1 and M2 type microglia/macrophages. M1 activation is 
the classical response of immune cells to infection or tissue injury, while the M2 
phenotype is characteristic for the alternative activation of immune immune cells in 
response to parasitic infections or allergens. Therefore, TSPO receptors 
measurement does not allow discrimination between these microglia phenotypes. 
More specific tracers, targeting one cell type or characteristic only to M1 or M2-
type inflammation, could allow more specific assessment of neuroinflammation by 
PET imaging. However, which markers can be considered characteristic for M1 or 
M2 activation is still debatable. Includible nitric oxide synthase (iNOS) is 
commonly used as a marker for M1 activation, while M2 activation seems to be 
more difficult to detect. Several markers of M2 activation are considered, for 
example C-Type Mannose Receptor 1 (CD206) and Hemoglobin-Haptoglobin 
Scavenger Receptor (CD163), early growth response protein 2 (Egr2) and arginase-
1 [45]. In vitro studies have shown that protein expression of many M2 markers is 
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low (e.g. arginase-1, CD206) or markers are non-selective (e.g. arginase-1). CD163 
has been proposed as a good M2 marker, but was shown to be unreliable when 
used alone. Therefore it is recommended for immunohistochemistry staining to 
analyze multiple markers for the M2 phenotype [46]. Investigation of new M1/M2 
markers is still in progress. For example, recent studies investigating expression 
patterns in different phenotypes of macrophages proposed CD38 and Egr2 as 
promising markers of M1 and M2 activation, respectively [47]. Molecules 
interacting with these markers may be considered as lead compounds for more 
specific tracers for inflammation. This, however, would require further validations. 
Moreover, immunohistochemistry markers are not always applicable for brain PET 
imaging. Recently, M2 activated macrophages were detected in tumors with PET, 
using [18F]Camelid Single-Domain Antibody Fragments in peripheral tissue tumors 
[48]. This method may be difficult to apply in brain imaging, since the passage of 
antibodies through blood brain barrier (BBB) is very limited. However, recent 
research has demonstrated a possibility to use antibody-based tracers in brain 
imaging [49]. 
In conclusion, the perfect tracer for imaging of neuroinflammation might be 
different for brain and peripheral imaging. In both cases, a high specificity, high 
signal to noise ratio and slow metabolism is desirable. For brain imaging, 
additionally a good passage of BBB is necessary. The TSPO receptor is not the 
optimal target and therefore other targets need to be found. Until then, TSPO 
seems to be the best-known target for brain imaging of neuroinflammation, 
although more sensitive tracers than PK11195 that are not sensitive to the TSPO 
polymorphism, are urgently awaited. 
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